Steve and Grant Frisken named in The Australian’s Top 100 Innovators List for 2021

September 2021

Cylite Pty Ltd., was honoured to have two of its founders, Steve and Grant Frisken recognised in “The List – 100 Innovators 2021”.

The List: 100 Innovators 2021 is curated and edited by Technology Editor David Swan and draws on the knowledge and expertise of The Australian’s specialist journalists along with a world-class advisory panel.

“I was surprised and delighted to discover we were recognised in this way” stated Dr. Steve Frisken, Chief Executive Officer of Cylite. “It is an honour to be named alongside my brother and recognised in this list of talented entrepreneurs”, said Grant Frisken, Cylite’s Chief Technology Officer.

Both Steve and Grant commented, “there is a talented team of people, mostly based in Melbourne, who have continued give 100% throughout these challenging times, working on some very novel and innovative technologies that we believe will significantly advance medical care within the ophthalmic space. All of the team at Cylite can be proud of this recognition.”

Article extract: Cylite’s 4th-generation Hyperparal­lel-OCT device is a diagnostic tool for ophthalmologists and optometrists that uses 3D spectral imaging tech­nology to measures full volume im­ages of the eye at more than 300,000 A-scans per second. CEO Steve Frisken and CTO Grant Frisken have more than 40 years of experience between them and hold a number of patents. The device was the winner of the Australian Engineering Excel­lence Award, with Engineers Aus­tralia Victoria Division manager Alesha Printz describing it as “A cut­ting-edge technology that has been designed, engineered and manufac­tured in Australia.”

Full access to the article (needs subscription) https://www.theaustralian.com.au/business/top-innovators

Declaration

This website is intended for use by healthcare professionals only. By clicking agree, you are declaring that you are a registered healthcare professional with an appropriate registration.

If you do not agree, you’ll not be able to view the content on this page.